Financial Conflict of Interest and Academic Influence Among Experts Speaking on Behalf of the Pharmaceutical Industry at the US Food and Drug Administration's Oncologic Drugs Advisory Committee Meetings  Austin Lammers, MD, Jonathan Edmiston, MPH, Victoria Kaestner, BA, Vinay Prasad, MD, MPH  Mayo Clinic Proceedings  Volume 92, Issue 7, Pages 1164-1166 (July 2017) DOI: 10.1016/j.mayocp.2017.04.014 Copyright © 2017 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 1 Simple univariate linear regression between industry payments and measures of research productivity: total publications, total citations, and h-index. Mayo Clinic Proceedings 2017 92, 1164-1166DOI: (10.1016/j.mayocp.2017.04.014) Copyright © 2017 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 2 The amount of payments made to 37 experts speaking on behalf of pharmaceutical companies. One person (not shown) met outlier criteria, with payments received of $2.8 million. Mayo Clinic Proceedings 2017 92, 1164-1166DOI: (10.1016/j.mayocp.2017.04.014) Copyright © 2017 Mayo Foundation for Medical Education and Research Terms and Conditions